NEW YORK (GenomeWeb News) – Molecular diagnostics firm Linkage Biosciences today announced it has raised $2.1 million in a Series B financing round.
The funds will be used to expand manufacturing capabilities, complete regulatory requirements in the US and Europe, and accelerate molecular tests to market, Zachary Antovich, CEO of Linkage, said in a statement.
Fisher Capital and Greenhouse Capital Partners led the round. All major existing investors, including Big Sky Partners, also were participants.
Linkage raised $2 million in a Series A round in 2009.
Based in San Francisco, Linkage's lead product is its LinkSeq HLA product line, which combines a proprietary software and chemistry platform along with real-time PCR instrumentation to provide "significant improvements in the analysis of complex genetic regions," such as an up-to 85 percent reduction in labor requirements, compared to current methods, Linkage said.